tbuckley/cabot-search huggingface dataset:
Abstract LB-69: Minnesota Ovarian Cancer Alliance
Authors: Kathleen A. Gavin
Journal: Cancer Research (2011)

Abstract The Minnesota Ovarian Cancer Alliance (MOCA) is a nonprofit organization whose mission is to create awareness regarding early warning signs that may be indicative of ovarian cancer; to develop and promote resources for support, networking and education for women diagnosed with ovarian cancer and their families; to unite and educate individuals, the medical community and organizations to achieve earlier diagnosis, better treatment and a cure for ovarian cancer; and to advance ovarian cancer research toward earlier diagnosis, better treatment, and ultimately, a cure. MOCA staff and members primarily serve as patient advocates and consumer reviewers to state and national gynecologic oncology research initiatives including the GOG, the Mayo Ovarian SPORE, the DOD, and others. MOCA funds ovarian cancer research, with the average grant award at around $70,000. To date, the organization has awarded $2.6 million to over 40 research projects in the last 10 years. MOCA also provides scholarships to support oncology nurses' attendance at national educational conferences. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-69. doi:10.1158/1538-7445.AM2011-LB-69
S67 COPD–in the NEWS!
Authors: LE Hodgson, S Bax, M Montefort, JP Zahra, R Venn, H Ranu, J Congleton
Journal: Thorax (2013)

<h3></h3> NICE<sup>1</sup> recommends ‘track and trigger’ systems for all adult acute hospital admissions and the RCP<sup>2</sup> advocates the use of the National Early Warning Score (NEWS) to promptly highlight high risk patients. In non-selected medical patients a higher admission NEWS correlates with higher mortality, with a step-wise increase as the score increases. Anecdotally patients with COPD have high rates of NEWS alerting. No studies have looked at the validity of the NEWS in COPD patients though the issue was raised in a previous abstract. We retrospectively interrogated an electronic observation database in our Trust (two acute sites) over a year (February 2012–January 2013). We compared acute medical unit (AMU) admissions aged over 50 years (n = 13,291) with patients admitted with a primary diagnosis of COPD (n = 1119). Despite a similar age profile (median 74 &amp; 77) and inpatient mortality (5.3% &amp; 6.2%), the COPD cohorts admission NEWS was double that of the AMU patients (median 4 vs 2). This difference persisted throughout admission to discharge. Admission NEWS showed a step-wise increase in mortality amongst the AMU patients. In contrast, the COPD cohort with NEWS of 5 or 6 had <i>lower</i> in-patient mortality compared to COPD patients scoring 2–4. NEWS of ≥7 is used to trigger urgent medical attention and 20% of patients with COPD fulfilled this criteria (compared to 6.6% of non-COPD patients). When NEWS score was ≥10, mortality in both groups was high (31.6% in COPD patients, 40% in AMU patients)(graph 1). In conclusion, we have shown that acute COPD patients have similar mortality to other emergency medical admissions yet persistently higher NEWS. This requires addressing possibly by adjusting the NEWS to take into account lower oxygen saturation targets in selected COPD patients (median 93% compared to 96% in AMU patients) and thus reduce over-alerting of those not necessarily at high risk of death. <h3>References</h3> Acutely ill patients in hospital. Recognition of and response to acute illness in adults in hospital. http://www.nice.org.uk/nicemedia/pdf/CG50FullGuidance.pdf National Early Warning Score (NEWS) Standardising the assessment of acute-illness severity in the NHS - Report of a working party July 2012 http://www.rcplondon.ac.uk/sites/default/files/documents/national-early-warning-score-standardising-assessment-acute-illness-severity-nhs.pdf
Abstract 3178: Identification and validation of markers for colon adenoma and adenocarcinoma
Authors: Kamini Sewda, Steven Enkemann, Robert J. Gillies, David L. Morse
Journal: Cancer Research (2011)

Abstract Colorectal cancer (CRC) is the second leading cause of cancer related deaths in the United States and Europe. The early detection and diagnosis of dysplastic and early neoplastic colonic lesions will improve survival and make possible curative treatments. Currently, this is best done with colonoscopy, which is expensive and requires a cathartic bowel prep that has led to low compliance. The goal of this study is to develop targeted molecular imaging agents for the early detection of colon cancer via targeted and potentially prepless colonography using CT or MRI contrast. Such agents can also be used to improve detection of lesions for removal during traditional colonoscopy. By gene expression profiling of DNA microarray data from patient samples of colon adenoma (n =39), adenocarcinoma (n = 432), inflammatory bowel disease (IBD) (n = 16) and unaffected gastrointestinal (GI) tract tissues (normal colon, n = 178 and other gastrointestinal tissues n = 32), we have identified 6 potential cell-surface targets that are highly expressed in colon adenomas and adenocarcinomas relative to unaffected GI tissues: TLR4, LY6G6D, GRM8, GPR56, SLCO1B3 and CLDN1. None of these markers alone cover 100% of the colon adenoma and adenocarcinoma samples surveyed, although combinations did. Nearly all (99.7%) of the adenoma and adenocarcinoma samples express at least one of the three markers TLR4, LY6G6D and CLDN1. One tumor did not express any of these markers. CSF3R and SLC6A14 are expressed exclusively in IBD, which is a risk factor for colon cancer. DNA microarray expression data for colon tumor cell lines (DIFI, SW-620, SW-480, HT-29, COLO-205, KM12, KM12S, HCT116, and HCT115) were also analyzed, and SW-620 and SW-480 cell lines were identified as expressing TLR4, LY6G6D, GPR56 and CLDN1. COLO-205 cells highly express GRM8 and KM12 cells express SLCO1B3. GPR56 and CLDN1 were broadly expressed amongst all cell lines. Validation of these markers for protein expression in patient tissue samples by immunohistochemistry is underway. Molecular imaging agents against validated targets are being developed for the potentially prepless and non-invasive detection of colon adenomas and adenocarcinomas using molecular colonography. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3178. doi:10.1158/1538-7445.AM2011-3178
1151 CONTINUED HIGH VIROLOGIC RESPONSE RATES WITH ACH-1625 DAILY DOSING PLUS PEGIFN-ALPHA 2A IN A 28-DAY AND 12-WEEK PHASE 2A TRIAL
Authors: F. Poordad, J. Lalezari, E. Lawitz, H. Van Vlierberghe, M. Shiffman, I. Jacobson, M. Kankam, V. Araya, R. Ghalib, M. Ryan, B. Bacon, S. Flamm, E. Godofsky, L. Hazan, F. Hinestrosa, P. Michielsen, P. Deltenre, H. Robison, L. Robarge, E. Olek
Journal: Journal of Hepatology (2012)
Resting State Depth and Saturation Density as Modulated by Tumor Promoters and Culture Conditions: Relationship to Chemical Transformation in C3H/10T½ Cells<xref ref-type="fn" rid="FN2">2</xref>
Authors: D Miska, H B Bosmann
Journal: JNCI Journal of the National Cancer Institute (1982)

With the use of cultures of C3H/10T1/2 fibroblasts, the relationships of saturation density and cell resting state (Go) depth to oncogenic transformation by 3-methylcholanthrene (MCA) were investigated. The tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA), caused a small increase in the saturation density, but saccharin (SAC), a suspected promoter, did not, Correspondingly, TPA tested positively as a promoter of transformation in a typical two-stage transformation assay with these cells while SAC did not. By altering the confluent-phase serum concentration and/or the medium renewal frequency of MCA-treated cultures, it was found that the magnitude of transformation for a given concentration of MCA was independent of the saturation density. Oscillations in this density were observed even when the medium was renewed as frequently as every 3 days, indicating that cell death and replacement occur during what is generally regarded to be a period of cellular stability. Neither TPA nor SAC blocked the cells from progressing into deeper resting states over time, as indicated by the prereplicative lag time after a medium change at 42 days. However, the serum concentration and medium renewal frequency did affect the resting state depth. Daily renewals with medium containing 10% serum blocked the resting state from deepening and kept the cells from achieving a saturation density. Under these circumstances, transformation was completely inhibited in MCA-treated cultures.
EXTENT OF ACUTE CONTRACTILE RECOVERY DURING BIVENTRICULAR PACING IS NOT ASSOCIATED WITH LONG-TERM FOLLOW-UP IN HEART FAILURE PATIENTS WHO UNDERGO RESYNCHRONIZATION THERAPY
Authors: Federica De Vecchi, Chiara Cavallino, Virginia Di Ruocco, Emanuela Facchini, Eraldo Occhetta, Andrea Magnani, Paolo Marino
Journal: Journal of the American College of Cardiology (2015)
Abstract 3239: Synergy of PIM1 kinase with c-MYC in prostate cancer
Authors: Jie Wang, Jongchan Kim, Meejeon Roh, Omar E. Franco, Erin Martinez, Simon W. Hayward, Marcia L. Wills, Sarki A. Abdulkadir
Journal: Cancer Research (2010)

Abstract The oncogenes PIM1 and c-MYC are frequently up-regulated in human prostate tumors. We found that PIM1 and c-MYC were co-expressed in human prostate cancer and were associated with higher Gleason scores. We next used a model of prostate regeneration coupled with lentiviral-mediated gene transfer to directly show that Pim1 dramatically enhanced c-MYC tumorigenicity in naïve adult mouse prostatic epithelium in a kinase-dependent manner. Microarray analysis revealed that many signaling pathways including MAPK, focal adhesion calcium signaling pathway were activated in MYC/Pim1 tumor. Knockdown of Pim1 in MYC/Pim1 tumor derived cell line reduced ERK and Akt phosphorylation. We further showed that targeting Pim1 by shRNA inhibited tumorigenicity in vitro and in vivo. Pim1 kinase inhibitor quercetagetin also inhibited cell growth in vitro. These results directly demonstrate that MYC and PIM1 cooperate in promoting tumor development. PIM1 can be considered as a drug target for human prostate cancer treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3239.
A Randomized, Double-Blind Study of Phenytoin for the Prevention of Post-Traumatic Seizures
Authors: Nancy R. Temkin, Sureyya S. Dikmen, Alan J. Wilensky, Jane Keihm, Sharon Chabal, H. Richard Winn
Journal: New England Journal of Medicine (1990)

Antiepileptic drugs are commonly used to prevent seizures that may follow head trauma. However, previous controlled studies of this practice have been inconclusive.
Cholecystitis and Diabetes Mellitus
Authors: Eldred D. Mundth
Journal: New England Journal of Medicine (1962)

MOST authorities agree that cholelithiasis associated with diabetes mellitus has a more serious prognosis than cholelithiasis in the nondiabetic patient. The reason commonly stated to support this contention is that complications of cholelithiasis associated with an inflammatory process have an increased morbidity and mortality in the patient with diabetes.The operative mortality with emergency surgery for acute complications of cholelithiasis in diabetic patients has been reported as 15 to 20 per cent, or four or five times as great as that for a similar group of nondiabetic patients.1 , 2 However, with elective surgery for uncomplicated cholelithiasis or chronic cholecystitis the operative . . .
P1-12-21: Adjuvant Trastuzumab Treatment without Adjuvant Chemotherapy in Early Breast Cancer.
Authors: P Dall, T Koch, G Lenzen, T Kuhn, C Hielscher, D Reichert, M Maasberg, P Ehscheidt, H Eustermann, G Fischer
Journal: Cancer Research (2011)

Abstract Background: Trastuzumab (T) is approved in most Western countries for the treatment of early, HER2+ breast cancer (BC) parallel or sequential to adjuvant chemotherapy (CT). Nevertheless, as in metastatic disease, the antibody seems to be used without chemotherapy in a selected group of HER2+ patients (pt). The purpose of this analysis is to characterize this subgroup as well as describe safety and efficacy outcome parameters in this German prospective observation trial. Methods: At present, 2870 patients (pts) have been enrolled and documented in this ongoing non-interventional study from 270 German centers. At data base closure for this analysis, sufficient documentation was available from 2422 eligible pts. Results: The proportion of pts receiving T without preceding or concomitant CT (noCT) was 180/2422 (7.4%). This subgroup was characterized by higher age (median 58 vs.56 in the CT group, p=0.0026; ≥70 years: 18%/10%), smaller primaries (pT1 49%/43%, p=0.11), more favorable grading (G3 45%/53%, p=0.045), a higher proportion of positive hormone receptor (67%/61%, p=0.096) and less radiotherapy (64%/79%, p&amp;lt;0.0001). The strong association to radiotherapy is probably due to the fact, that the choice of this additional modality reflects the overall risk assessment of the pt. In contrast, there was no difference in nodal involvement (pN0: 52%/51%; positive nodes: mean 2.5/2.4). In multivariate analysis (logistic regression model, not incorporating radiotherapy), hormone receptor status is not predictive (p=0.41), while age ≥65 (p=0.0011), grade 1/2 (p=0.046) and pT1 (p=0.089) independently remain at least borderline significant. The mean number of T administrations was 18 and the median duration of T therapy was 12 months in the noCT group as well as the CT group. 57% of the noCT pts received adjuvant endocrine therapy. In the CT group, 81% received anthracyclines and 61% taxanes. Based on a still low number of only 13 observed events in the noCT group, no differences in relapse-free survival could be detected (p=0.38). Pathological cardiac findings in the pt's history was not predictive of therapy selection (6%/7%) and were also similarly distributed at the end of T therapy (7%/8%). Cardiac function disorders of CTC grade 3/4 were reported in 1% of both groups, across all grades slightly less frequent in the noCT group (2.8%/4.0%). Conclusions: A small, but distinct group of early BC pts without adjuvant chemotherapy receives T treatment for HER2+ disease. These patients are characterized by higher age and favorable primary tumor staging and grading, but not by cardiac comorbidities. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-12-21.
PMO-207 Changing trends in upper and lower gastrointestinal bleeding over a 13-years period
Authors: C Smith, J M Thomson, A Fraser, B Vijayan, J S Leeds
Journal: Gut (2012)

<h3>Introduction</h3> Acute gastrointestinal (GI) bleeding is a common medical emergency associated with significant mortality and morbidity. Recent studies suggest that the incidence of upper GI bleeding (UGIB) has decreased mainly due to reduction in peptic ulcer disease. Trends for lower GI bleeding (LGIB) are less well defined and therefore the burden on health services is unknown. The aim of this study was to examine the trends in all types of GI bleeding presenting to our bleeding unit over a 13-year period. <h3>Methods</h3> Our Gastrointestinal Bleeding Unit opened in October 1991 and serves a population of around 600 000. The unit admits patients with both upper (UGIB) and lower (LGIB) bleeding and maintains a prospective database of all admissions. The database was analysed for yearly admissions over the period 1991–2004 with respect to total number of admissions and then stratified by bleeding source, age, gender and diagnosis. Age, gender, bleeding source and disease specific rates were calculated. <h3>Results</h3> 12 572 patients (median age 66, 7028 males) were admitted to the unit over the period October 1991–October 2004. 9544 presented with symptoms of UGIB and 2508 with symptoms of LGIB with 520 patients being unclassified due to a mixture of symptoms. Overall numbers of admissions increased from 728 in the first year to 1003 in year six then reached a plateau thereafter around 950 per year. Overall 30-day mortality was 9.7% (8.7–10.8) for UGIB and 11.4% (9.2–14.1) for LGIB and there was no change in rebleeding rates. Median age increased significantly from 64 years to 68 years (p&lt;0.001) over this period mirrored by increasing age in UGIB (63 to 65 years, p&lt;0.001) but no significant difference in LGIB. Patients presenting with LGIB were significantly older than those presenting with UGIB (70 vs 64, p&lt;0.001) and were more likely to be female (OR 1.64, 95% CI 1.5 to 1.8, p&lt;0.001). With respect to UGIB, there was a non significant increase in admissions overall but there was a rise in variceal bleeding (OR 2.5, 95% CI 1.5 to 4.4, p=0.005) but a reduction in bleeding peptic ulcers (OR 0.65, 95% CI 0.49 to 0.87, p=0.039) particularly in males age &lt;40 years. There was a significant increase in the numbers of admission due to LGIB (p&lt;0.001) predominantly due to inflammatory bowel disease (p=0.04), haemorrhoidal bleeding (p=0.001) and ischaemic colitis (p=0.0016). <h3>Conclusion</h3> There has been an increase in numbers of patients admitted with GI bleeding and this population is significantly older over time. There has been a decline in peptic ulcer bleeding but a rise in variceal cases. Admissions overall for GI bleeding have increased mainly due to a significant rise in LGIB mainly accounted for by IBD, haemorrhoids and ischaemic colitis. <h3>Competing interests</h3> None declared.
Abstract 3088: Mammalian sterile-20 like kinase 1(Mst1) upregulates cyclin D1 to promote hepatocellular carcinoma cell growth
Authors: Yuen Keng Ng, Vivian Wai Yan Lui, Alfred Sze Lok Cheng, George Gong Chen, Paul Bo-san Lai
Journal: Cancer Research (2010)

Abstract Although hepatocellular carcinoma (HCC) is highly related to the chronic infection of hepatitis B or C viruses, the progression of the malignancies is caused by the increased proliferation of the HCC cells. The proliferation of tumor cells is usually resulted from dysregulations in cell cycle progression or apoptosis induction. Current evidence indicates that the cytoplasmic serine/threonine kinase Mammalian Sterile-20 like kinase 1 (Mst1) suppresses HCC development by inactivating the oncoprotein YAP65 in normal livers. Furthermore, upon DNA damage, the caspase cleavage of the full-length cytoplasmic Mst1 proteins is activated, which then leads to Mst1 nuclear translocation and apoptosis induction via transcriptional activation of the Forkhead tumor suppressor Foxo3a. Using an HCC cell line model, the Hep3B cells, we found that transient transfection of Mst1 did not induce apoptosis, but rather enhanced the cellular proliferation by 74% within 2 days after transfection. The growth-promoting activity of Mst1 in the HCC cells was confirmed as Hep3B cell growth was significantly reduced by transient expression of the Mst1 kinase dead mutant (26% reduction) or Mst1 specific shRNAs (62% reduction). The Mst1-induced cell proliferation was further evidenced by the presence of Ki67 nuclear staining in the transfected Hep3B cells while the cells expressing the kinase dead mutant of Mst1 did not have Ki67 nuclear staining. Moreover, Western blot analyses showed that phosphorylation of YAP65 was not dependent upon Mst1 overexpression, suggesting that the hippo pathway was not involved in the Mst1 induced cell proliferation. Interestingly, Western blotting showed that such a growth-promoting activity of Mst1 in Hep3B cells was associated with a sustained upregulation of Cyclin D1 expression, an important marker for proliferation, after Mst1 overexpression. Our findings suggest that an alteration of Mst1 function exists in HCC cells, which drives aberrant HCC proliferation via Cycin D1 upregulation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3088.
BODE plus DOSE plus Pa<sub>O<sub>2</sub></sub> equals DO RE MI BOX?
Authors: Rupert C. Jones, Samantha Harding, Michael E. Hyland, Gavin C. Donaldson, Jadwiga A. Wedzicha, Niels H. Chavannes, Kozui Kida, David Price
Journal: American Journal of Respiratory and Critical Care Medicine (2010)
SP0023 Role of microparticles in inflammation
Authors: J. Distler
Journal: Annals of the Rheumatic Diseases (2013)

Microparticles are a heterogeneous population of small membrane-coated vesicles that represent subcellular elements for cell signaling and intercellular communication in inflammation. Microparticles can be released by virtually all cell types upon activation or apoptosis although, depending upon their origin, they can vary in size, biochemical composition and biological effects. Microparticles contain a wide array of biologically active molecules such as proteins, lipids and nucleic acids. Furthermore, microparticles can transfer cytokines, receptors, RNA and DNA to modulate the properties of target cells. As MPs appear in the blood in increased numbers in many rheumatic diseases, they may also represent novel biomarkers. This talk will summarize the current knowledge about microparticles as regulators of inflammation in rheumatic diseases. <h3>Disclosure of Interest</h3> None Declared
58 HRas SIGNAL TRANSDUCTION MEDIATES HEPATITIS C VIRUS CELL ENTRY BY TRIGGERING THE ASSEMBLY OF THE HOST TETRASPANIN RECEPTOR COMPLEX
Authors: L. Zona, J. Lupberger, C. Thumann, N.S. Ahmed-Adrar, H.J. Harris, F.H.T. Duong, M.H. Heim, P. Bachellier, M.B. Zeisel, D. Samuel, F. le Naour, J.A. McKeating, T.F. Baumert
Journal: Journal of Hepatology (2013)
<i>Candidatus</i>Rickettsia tarasevichiae Infection in Eastern Central China
Authors: Wei Liu, Hao Li, Qing-Bin Lu, Ning Cui, Zhen-Dong Yang, Jian-Gong Hu, Ya-Di Fan, Chen-Tao Guo, Xiao-Kun Li, Ya-Wei Wang, Kun Liu, Xiao-Ai Zhang, Lan Yuan, Pu-Yu Zhao, Shu-Li Qin, Wu-Chun Cao
Journal: Annals of Internal Medicine (2016)

Background: Human infection with Candidatus Rickettsia tarasevichiae (CRT) was first reported in northeastern China in 2012. Objective: To describe the clinical spectrum and laboratory findings of patients infected with CRT in eastern central China. Design: Case series. Setting: A sentinel hospital for severe fever with thrombocytopenia syndrome (SFTS) in eastern central China in 2014. Participants: Hospitalized patients with SFTS-like illness. Measurements: Molecular and serologic tests were performed to diagnose CRT infection. Data about clinical manifestations and laboratory findings were retrieved from medical records. Results: 56 of 733 assessed patients had CRT based on polymerase chain reaction and sequencing. All patients presented with nonspecific manifestations, including fever (96%), malaise (88%), myalgia (57%), cough (25%), and dizziness (14%). Only 2 patients had rash. Further, 16% had eschar, 29% had lymphadenopathy, 100% had gastrointestinal symptoms, 34% had neurologic symptoms, 43% had hemorrhagic manifestations, and 23% had signs of plasma leakage. Thrombocytopenia was observed in 70%, leukopenia in 59%; lymphopenia in 45%; and elevated levels of lactate dehydrogenase in 82%, aspartate aminotransferase in 70%, alanine aminotransferase in 54%, and creatinine kinase in 46%. Co-infection with SFTS virus was documented in 66% patients, and 8 of the 56 patients died. Limitations: Patients with CRT were not treated for infection because they were retrospectively identified. This was not a population-based study, and the results cannot be generalized to all patients with CRT. Conclusion: Candidatus R tarasevichiae infection should be considered in the differential diagnosis of febrile patients with SFTS-like illness in endemic areas. Primary Funding Source: National Natural Science Foundation of China.